Physician profile
Donald A Molony
NPI 1073531380
$70,251.47
in general payments reported to CMS, 2019-2025
20 companies · $34K in 2025
The $34K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,223 · 2021: $2,184 · 2022: $4,855 · 2023: $8,519 · 2024: $2,743 · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $3,429 · Food and Beverage: $3,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,602.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,361.50 |
| Travel and Lodging | $3,428.61 |
| Food and Beverage | $3,159.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $32,830.90 | 2019-2025 | Voyxact, Jynarque |
| Fresenius USA Marketing, INC. | $17,393.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $7,937.92 | 2023-2025 | |
| Travere Therapeutics, INC. | $6,727.04 | 2022-2025 | |
| Vifor Pharma, INC. | $2,211.77 | 2021-2023 | Veltassa |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | $1,608.53 | 2019 | |
| Aurinia Pharma U.S., INC. | $354.21 | 2021-2023 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $265.72 | 2025 | |
| Nxstage Medical, INC. | $141.30 | 2022-2025 | Nxstage System One, Nxstage Pureflow Solution |
| Astrazeneca Pharmaceuticals Lp | $129.73 | 2019-2025 | Farxiga |
| Idorsia Pharmaceuticals US INC | $124.40 | 2025 | Tryvio |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $122.72 | 2019 | |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.76 | 2024-2025 | Jardiance |
| Genzyme Corporation | $58.45 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.00 | 2022 | |
| Ardelyx, INC. | $39.80 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $31.30 | 2021-2024 | Rayaldee |
| Cormedix INC. | $29.09 | 2025 | Defencath |
| Calliditas Therapeutics US INC. | $17.83 | 2025 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Molony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.